Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.00
- Piotroski Score 4.00
- Grade Sector Perform
- Symbol (BEAM)
- Company Beam Therapeutics Inc.
- Price $23.59
- Changes Percentage (-3.68%)
- Change -$0.9
- Day Low $23.33
- Day High $24.71
- Year High $49.50
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
- Last Earnings 01/23/2014
- Ex-Dividend for 5/16 Dividend 02/04/2014
- Dividend Payable 03/03/2014
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $62.00
- High Stock Price Target $69.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.60
- Trailing P/E Ratio -14.51
- Forward P/E Ratio -14.51
- P/E Growth -14.51
- Net Income $-132,526,999
Income Statement
Quarterly
Annual
Latest News of BEAM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Beam Global Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Profit margin rose to 11% from a previous net loss in 3Q 2023 due to reduced expenses. Revenue fell short of analyst estimates by 25%, but earnings per share surpassed expectations....
By Yahoo! Finance | 4 days ago -
Beamr Imaging Ltd. (BMR): Among the Best AI Penny Stocks to Buy According to Analysts
Bokeh Capital Partners' Kim Forrest discusses the advantages of smaller, targeted AI solutions over large language models, emphasizing their practicality and effectiveness. She highlights investment o...
By Yahoo! Finance | 1 week ago -
Walmart's early Black Friday sale is live! Save up to 70% on Lego, Henckels, Sunbeam and more
Sign up for a Walmart+ membership on their website to enjoy benefits like free shipping and exclusive early access to special promotions. Shop early Black Friday deals now or access them without a mem...
By USA Today | 1 week ago
